Tty Biopharm Company Limited · TPEX:4105
Tty Biopharm — Q1-Q3 2025 Earnings Presentation
13 slides from Tty Biopharm's earnings presentation, Nov 26, 2025
Slide 1: TTY Biopharm Operational Results Report
TTY Biopharm 4105 Operational Results Report 2025.11.26
Slide 2: Disclaimer
Disclaimer This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, TTY Biopharm cautions that this foregoing list of factors is not ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’,
Slide 3: Operational Highlights
Operational Results Report Q1~Q3/2025 Operational Highlights Q1~Q3/2025 Financial Performance 01 Q1~Q3/2025 Operational Highlights 2026 Outlook 2
Slide 4: TTY Strategy Enhances Operational Performance
TTY Strategy Enhances Operational Performance 營運成果報告 Revenue Overview Q1~Q3/2025 Operational Highlights Consolidated Revenue 5,000 4,791 6 YoY growth +15% 47.9 billion 4,182 Q1~Q3/2025 4,000 5.05 5 Financial Performance 3.68 3,000 4 Consolidated Operating Profit 2,000 3 2026 Outlook 1,346 YoY growth
Slide 5: Market Development Highlights
Market Development Highlights 16.8% 12.8% 10.0% 營運成果報告 6.8% 2024 2025Q3 Export ratio Export US ratio Q1~Q3/2025 Operational Highlights Q1~Q3/2025 Financial Performance 2026 Outlook Strong growth in overseas sales Flu vaccine sales driven Significant Achievements in Self- both public & private funded
Slide 6: Three Arrows of Operation with Outstanding Results
Three Arrows of Operation with Outstanding Results 營運成果報告 Q1~Q3/2025 Operational Highlights Q1~Q3/2025 Financial Performance 2026 Outlook 5
Slide 7: OkaBIK Varicella Vaccine
OkaBIK Varicella Vaccine 營運成果報告 In addition to distributing The varicella vaccine is a Q1~Q3/2025 routine vaccine, with the Operational CSL Seqirus cell influenza first dose subsidized by the Highlights vaccine and adjuvanted government. influenza vaccine, TTY continues to expand Bidding will commen
Slide 8: Product Pipeline: Self-develop, License-in, Cooperation
Product Pipeline: Self-develop, License-in, Cooperation 營運成果報告 • Alliance with international partners to strengthen the advantage of the product portfolio • Joint-develop specialty of generic drugs with international partners and expand overseas markets Q1~Q3/2025 Operational Highlights Oncology 202
Slide 9: Q1~Q3/2025 Financial Performance
Operational Results Report Q1~Q3/2025 Operational Highlights Q1~Q3/2025 Financial Performance 02 Q1~Q3/2025 Financial Performance 2026 Outlook 8
Slide 10: Q1~Q3/2025 Financial Performance
Q1~Q3/2025 Financial Performance Operational Results Report Income Statement 2025 2024 YoY （Unit: NT Thousand, Q1~Q3 Q1~Q3 % Financial Performance except EPS） Q1~Q3/2025 Net Sales 4,790,870 4,181,720 15% • YoY consolidated revenue was 47.9 billion, +15% due to Operational the high growth of overseas
Slide 11: Q1~Q3/2025 Steady Revenue Growth
Q1~Q3/2025 Steady Revenue Growth Operational Results Report Q1~Q3/2025 Revenue Breakdown Q1~Q3/2025 Revenue Growth Q1~Q3/2025 Operational Revenue (NT Mn) Highlights Product Category % 4,900 -26 21% 4,700 63 3 4,791 Oncology 150 Q1~Q3/2025 205 3% 4,500 Financial Intensive Care 37% Performance 4,300 2
Slide 12: 2026 Outlook
Operational Results Report Q1~Q3/2025 Operational Highlights Q1~Q3/2025 Financial Performance 03 2026 Outlook 2026 Outlook 11
Slide 13: Expanding collaboration & overseas market, Licensing In & Self-developed
2026年度展望 營運成果報告 1 • Lipo-AB: -Expected to obtain licenses from Saudi Arabia, Australia, and Jordan -Deploy the market in Southeast Asia and South America Q1~Q3/2025 Expanding collaboration & • Leavdo launched in Singapore Operational • Continue to cultivate Southeast Asian markets such as Vietnam an
TTY Biopharm Company — Q1-Q3 2025 Earnings Presentation on 6ix